본문 바로가기
KERD
논문KCI 등재

Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers

김시현|한세원|차용준
대한암학회 (Korean Cancer Association)|2023.04|Cancer Research and Treatment|제55권 제2호|pp. 367-384|DOI 10.4143/crt.2023.446

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

MutationHigh-throughput nucleotide sequencingMinimal residual diseaseCirculating tumor DNAMolecular profiling
주제분류의학일반

초록

Plasma circulating tumor DNA (ctDNA) sequencing has demonstrated clinical utility for tumor molecular profiling at initial diagnosis or tumor progression in advanced solid cancers and is being rapidly incorporated into the clinical practice guidelines, including non–small cell lung and breast cancer. Despite relatively low sensitivity, plasma ctDNA sequencing has several advantages over tissue-based assays, including ease of sampling, rapid turnaround time, repeatability, and the ability to overcome spatial heterogeneity, which makes it ideal for investigating acquired resistance and monitoring tumor evolution and dynamics. With technological advancement and declining costs, the clinical application of plasma ctDNA is expanding, and numerous ongoing clinical trials are examining its potential to guide the management of advanced, localized, and even preclinical cancers of various tumor types. The ability of plasma ctDNA analysis to detect minimal residual disease following curative treatment in the absence of clinical disease is among its most promising attributes. Plasma ctDNA sequencing can also facilitate the conduct of clinical trials and drug development, particularly in immunotherapy. In order to incorporate plasma ctDNA sequencing for clinical decision-making, it is important to understand the preanalytical and analytical factors that may affect its sensitivity and reliability.

Abstract

Plasma circulating tumor DNA (ctDNA) sequencing has demonstrated clinical utility for tumor molecular profiling at initial diagnosis or tumor progression in advanced solid cancers and is being rapidly incorporated into the clinical practice guidelines, including non–small cell lung and breast cancer. Despite relatively low sensitivity, plasma ctDNA sequencing has several advantages over tissue-based assays, including ease of sampling, rapid turnaround time, repeatability, and the ability to overcome spatial heterogeneity, which makes it ideal for investigating acquired resistance and monitoring tumor evolution and dynamics. With technological advancement and declining costs, the clinical application of plasma ctDNA is expanding, and numerous ongoing clinical trials are examining its potential to guide the management of advanced, localized, and even preclinical cancers of various tumor types. The ability of plasma ctDNA analysis to detect minimal residual disease following curative treatment in the absence of clinical disease is among its most promising attributes. Plasma ctDNA sequencing can also facilitate the conduct of clinical trials and drug development, particularly in immunotherapy. In order to incorporate plasma ctDNA sequencing for clinical decision-making, it is important to understand the preanalytical and analytical factors that may affect its sensitivity and reliability.

참고문헌 (130)

  1. 윤신교, "Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group", Cancer Research and Treatment, 54(1), pp.1~9 (2022), 대한암학회[DOI]
  2. Mosele F, "Recommendations for the use of next-generation sequencing(NGS)for patients with metastatic cancers : a report from the ESMO Precision Medicine Working Group", Ann Oncol, 31, pp.1491~1505 (2020)
  3. Chakravarty D, "Somatic genomic testing in patients with metastatic or advanced cancer : ASCO provisional clinical opinion", J Clin Oncol, 40, pp.1231~1258 (2022)
  4. Pascual J, "ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer : a report from the ESMO Precision Medicine Working Group", Ann Oncol, 33, pp.750~768 (2022)
  5. Corcoran RB, "Application of cell-free DNA analysis to cancer treatment", N Engl J Med, 379, pp.1754~1765 (2018)
  6. Imai M, "Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors", Cancer Sci, 113, pp.3646~3656 (2022)
  7. Dasari A, "ctDNA applications and integration in colorectal cancer : an NCI Colon and Rectal-Anal Task Forces whitepaper", Nat Rev Clin Oncol, 17, pp.757~770 (2020)
  8. Rolfo C, "Liquid biopsy for advanced NSCLC : a consensus statement From the International Association for the Study of Lung Cancer", J Thorac Oncol, 16, pp.1647~1662 (2021)
  9. Siravegna G, "How liquid biopsies can change clinical practice in oncology", Ann Oncol, 30, pp.1580~1590 (2019)
  10. Kustanovich A, "Life and death of circulating cell-free DNA", Cancer Biol Ther, 20, pp.1057~1067 (2019)
  11. Zhang Y, "Pan-cancer circulating tumor DNA detection in over 10, 000 Chinese patients", Nat Commun, 12, pp.11~ (2021)
  12. Elazezy M, "Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management", Comput Struct Biotechnol J, 16, pp.370~378 (2018)
  13. Mouliere F, "Enhanced detection of circulating tumor DNA by fragment size analysis", Sci Transl Med, 10, pp.eaat4921~ (2018)
  14. Markus H, "Refined characterization of circulating tumor DNA through biological feature integration", Sci Rep, 12, pp.1928~ (2022)
  15. Diehl F, "BEAMing : single-molecule PCR on microparticles in water-in-oil emulsions", Nat Methods, 3, pp.551~559 (2006)
  16. Hindson BJ, "High-throughput droplet digital PCR system for absolute quantitation of DNA copy number", Anal Chem, 83, pp.8604~8610 (2011)
  17. Herberts C, "Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer", Nature, 608, pp.199~208 (2022)
  18. Zugazagoitia J, "Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping", Ann Oncol, 30, pp.290~296 (2019)
  19. Nakamura Y, "Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer : SCRUM-Japan GI-SCREEN and GOZILA studies", Nat Med, 26, pp.1859~1864 (2020)
  20. Turner NC, "Circulating tumour DNA analysis to direct therapy in advanced breast cancer(plasmaMATCH) : a multicentre, multicohort, phase 2a, platform trial", Lancet Oncol, 21, pp.1296~1308 (2020)
  21. Leighl NB, "Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer", Clin Cancer Res, 25, pp.4691~4700 (2019)
  22. Siravegna G, "Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients", Nat Med, 21, pp.795~801 (2015)
  23. Vidal J, "Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients", Ann Oncol, 28, pp.1325~1332 (2017)
  24. Grasselli J, "Concordance of blood-and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer", Ann Oncol, 28, pp.1294~1301 (2017)
  25. Schmiegel W, "Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients : concordance of results from circulating tumor DNA and tissue-based RAS testing", Mol Oncol, 11, pp.208~219 (2017)
  26. Manca P, "The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer", Clin Cancer Res, 27, pp.2505~2514 (2021)
  27. van Helden EJ, "RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer", Mol Oncol, 13, pp.2361~2374 (2019)
  28. Lim Y, "Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR", Sci Rep, 11, pp.16333~ (2021)
  29. Nakamura Y, "Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer : a phase 2 trial", Nat Med, 27, pp.1899~1903 (2021)
  30. Nakamura Y, "Clinical validity of plasma-based genotyping for microsatellite instability assessment in advanced GI cancers : SCRUM-Japan GOZILA substudy", JCO Precis Oncol, 6, pp.e2100383~ (2022)
  31. Wang Z, "Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment", J Immunother Cancer, 8, pp.e001297~ (2020)
  32. Kim ES, "Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer : the phase 2B-F1RST trial", Nat Med, 28, pp.939~945 (2022)
  33. Dawson SJ, "Analysis of circulating tumor DNA to monitor metastatic breast cancer", N Engl J Med, 368, pp.1199~1209 (2013)
  34. Tie J, "Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer", Ann Oncol, 26, pp.1715~1722 (2015)
  35. Parikh AR, "Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers", Clin Cancer Res, 26, pp.1877~1885 (2020)
  36. Kim S, "Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment", Br J Cancer, 127, pp.898~907 (2022)
  37. Kruger S, "Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer", Ann Oncol, 29, pp.2348~2355 (2018)
  38. Ricciuti B, "Early plasma circulating tumor DNA(ctDNA)changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer(NSCLC)", J Immunother Cancer, 9, pp.e001504~ (2021)
  39. Goldberg SB, "Early assessment of lung cancer immunotherapy response via circulating tumor DNA", Clin Cancer Res, 24, pp.1872~1880 (2018)
  40. Hrebien S, "Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial", Ann Oncol, 30, pp.945~952 (2019)
  41. O’Leary B, "Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer", Nat Commun, 9, pp.896~ (2018)
  42. Lo YM, "Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma", Cancer Res, 60, pp.2351~2355 (2000)
  43. Sanz-Garcia E, "Monitoring and adapting cancer treatment using circulating tumor DNA kinetics : current research, opportunities, and challenges", Sci Adv, 8, pp.eabi8618~ (2022)
  44. Misale S, "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer", Nature, 486, pp.532~536 (2012)
  45. Montagut C, "Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer", Nat Med, 18, pp.221~223 (2012)
  46. Velimirovic M, "Rising circulating tumor DNA as a molecular biomarker of early disease progression in metastatic breast cancer", JCO Precis Oncol, 4, pp.1246~1262 (2020)
  47. Frank MS, "Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of patients with advanced non–small cell lung cancer", Cancer Res Commun, 2, pp.1174~1187 (2022)
  48. Bidard FC, "Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy(PADA-1) : a randomised, open-label, multicentre, phase 3 trial", Lancet Oncol, 23, pp.1367~1377 (2022)
  49. Borcoman E, "Novel patterns of response under immunotherapy", Ann Oncol, 30, pp.385~396 (2019)
  50. Bratman SV, "Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab", Nat Cancer, 1, pp.873~881 (2020)
  51. Zhang Q, "Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade", Cancer Discov, 10, pp.1842~1853 (2020)
  52. Cabel L, "Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy : a proof-of-concept study", Ann Oncol, 28, pp.1996~2001 (2017)
  53. Lee JH, "Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies", JAMA Oncol, 4, pp.717~721 (2018)
  54. Topham JT, "Circulating tumor DNA identifies diverse landscape of acquired resistance to anti-epidermal growth factor receptor therapy in metastatic colorectal cancer", J Clin Oncol, 41, pp.485~496 (2023)
  55. Strickler JH, "Genomic landscape of cell-free DNA in patients with colorectal cancer", Cancer Discov, 8, pp.164~173 (2018)
  56. Parikh AR, "Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers", Nat Med, 25, pp.1415~1421 (2019)
  57. National Comprehensive Cancer Network, "NCCN clinical practice guidelines in oncology. Non-small cell lung cancer. Version 2.2023", National Comprehensive Cancer Network, ~ (2023)
  58. National Comprehensive Cancer Network, "NCCN clinical practice guidelines in oncology. Breast cancer. Version 2.2023", National Comprehensive Cancer Network, ~ (2023)
  59. Cremolini C, "Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan : a phase 2 single-arm clinical trial", JAMA Oncol, 5, pp.343~350 (2019)
  60. Sartore-Bianchi A, "Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer : the phase 2 CHRONOS trial", Nat Med, 28, pp.1612~1618 (2022)
  61. "Metastatic colorectal cancer (RAS-wildtype) after response to first-line treatment with FOLFIR plus cetuximab (AIO-KRK-0114). Report No. NCT02934529" (2021)[URL]
  62. Nakajima H, "REMARRY and PURSUIT trials : liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor(EGFR)therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer", BMC Cancer, 21, pp.674~ (2021)
  63. Strickler JH, "PULSE : a randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer(mCRC)", J Clin Oncol, 39(3 Suppl), pp.TPS143~ (2021)
  64. Diehl F, "Circulating mutant DNA to assess tumor dynamics", Nat Med, 14, pp.985~990 (2008)
  65. Beaver JA, "Detection of cancer DNA in plasma of patients with early-stage breast cancer", Clin Cancer Res, 20, pp.2643~2650 (2014)
  66. Garcia-Murillas I, "Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer", Sci Transl Med, 7, pp.302ra133~ (2015)
  67. Tie J, "Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer", Sci Transl Med, 8, pp.346ra92~ (2016)
  68. Chaudhuri AA, "Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling", Cancer Discov, 7, pp.1394~1403 (2017)
  69. Lee B, "Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer", Ann Oncol, 30, pp.1472~1478 (2019)
  70. Christensen E, "Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma", J Clin Oncol, 37, pp.1547~1557 (2019)
  71. Reinert T, "Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer", JAMA Oncol, 5, pp.1124~1131 (2019)
  72. Powles T, "ctDNA guiding adjuvant immunotherapy in urothelial carcinoma", Nature, 595, pp.432~437 (2021)
  73. Henriksen TV, "Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences", Clin Cancer Res, 28, pp.507~517 (2022)
  74. Huffman BM, "Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers", JCO Precis Oncol, 6, pp.e2200420~ (2022)
  75. Parikh AR, "Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer", Clin Cancer Res, 27, pp.5586~5594 (2021)
  76. Han SW, "381P A tumor-informed, hybrid-capture based ctDNA assay for minimal residual disease(MRD)detection in colorectal cancer(CRC)patients after curative surgery", Ann Oncol, 33(Suppl 7), pp.S710~1 (2022)
  77. Kotaka M, "Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan", J Clin Oncol, 40(4 Suppl), pp.9~ (2022)
  78. Tie J, "Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer", N Engl J Med, 386, pp.2261~2272 (2022)
  79. Folprecht G, "The CIRCULATE trial : circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation(AIO-KRK-0217)", Clin Colorectal Cancer, 21, pp.170~174 (2022)
  80. Sahin IH, "Minimal residual disease-directed adjuvant therapy for patients with early-stage colon cancer : CIRCULATE-US", Oncology(Williston Park), 36, pp.604~608 (2022)
  81. Taniguchi H, "CIRCULATE-Japan : circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer", Cancer Sci, 112, pp.2915~2920 (2021)
  82. Schraa SJ, "Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer(MEDOCC-CrEATE) : study protocol for a trial within a cohort study", BMC Cancer, 20, pp.790~ (2020)
  83. Wan JC, "Liquid biopsies for residual disease and recurrence", Med(N Y), 2, pp.1292~1313 (2021)
  84. Moding EJ, "Detecting liquid remnants of solid tumors : circulating tumor DNA minimal residual disease", Cancer Discov, 11, pp.2968~2986 (2021)
  85. Turner NC, "Results of the c-TRAK TN trial : a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate-and high-risk early-stage triple-negative breast cancer", Ann Oncol, 34, pp.200~211 (2023)
  86. Liu W, "Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA", EBioMedicine, 78, pp.103945~ (2022)
  87. Radovich M, "Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer : preplanned secondary analysis of the BRE12-158 randomized clinical trial", JAMA Oncol, 6, pp.1410~1415 (2020)
  88. McDuff SG, "Circulating tumor DNA predicts pathologic and clinical outcomes following neoadjuvant chemoradiation and surgery for patients with locally advanced rectal cancer", JCO Precis Oncol, 5 (2021)
  89. Vidal J, "Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer : a biomarker study from the GEMCAD 1402 trial", Clin Cancer Res, 27, pp.2890~2898 (2021)
  90. Magbanua MJ, "Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival", Ann Oncol, 32, pp.229~239 (2021)
  91. Khakoo S, "MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer", Clin Cancer Res, 26, pp.183~192 (2020)
  92. Li S, "Circulating tumor DNA predicts the response and prognosis in patients with early breast cancer receiving neoadjuvant chemotherapy", JCO Precis Oncol, 4 (2020)
  93. McDonald BR, "Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer", Sci Transl Med, 11, pp.eaax7392~ (2019)
  94. Tie J, "Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer : a prospective biomarker study", Gut, 68, pp.663~671 (2019)
  95. Cabalag CS, "Potential clinical utility of a targeted circulating tumor DNA assay in esophageal adenocarcinoma", Ann Surg, 276, pp.e120~6 (2022)
  96. Zhou Q, "Persistence of ctDNA in patients with breast cancer during neoadjuvant treatment is a significant predictor of poor tumor response", Clin Cancer Res, 28, pp.697~707 (2022)
  97. Wo JY, "Results and molecular correlates from a pilot study of neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal adenocarcinomas", Clin Cancer Res, 27, pp.6343~6353 (2021)
  98. Cailleux F, "Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse", JCO Precis Oncol, 6, pp.e2200148~ (2022)
  99. Wang Y, "Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer : a prospective cohort study", PLoS Med, 18, pp.e1003741~ (2021)
  100. Tie J, "Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases : a prospective cohort study", PLoS Med, 18, pp.e1003620~ (2021)
  101. Forde PM, "Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer", N Engl J Med, 386, pp.1973~1985 (2022)
  102. Lee WC, "Background and significance of Korean national cancer screening guideline revision", J Korean Med Assoc, 58, pp.274~276 (2015)
  103. Smith RA, "Cancer screening in the United States, 2019 : a review of current American Cancer Society guidelines and current issues in cancer screening", CA Cancer J Clin, 69, pp.184~210 (2019)
  104. Cohen JD, "Detection and localization of surgically resectable cancers with a multi-analyte blood test", Science, 359, pp.926~930 (2018)
  105. Lennon AM, "Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention", Science, 369, pp.eabb9601~ (2020)
  106. Liu MC, "Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA", Ann Oncol, 31, pp.745~759 (2020)
  107. Klein EA, "Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set", Ann Oncol, 32, pp.1167~1177 (2021)
  108. Jamshidi A, "Evaluation of cell-free DNA approaches for multi-cancer early detection", Cancer Cell, 40, pp.1537~1549 (2022)
  109. Shen SY, "Sensitive tumour detection and classification using plasma cell-free DNA methylomes", Nature, 563, pp.579~583 (2018)
  110. Hackshaw A, "New genomic technologies for multi-cancer early detection : rethinking the scope of cancer screening", Cancer Cell, 40, pp.109~113 (2022)
  111. Hackshaw A, "Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK", Br J Cancer, 125, pp.1432~1442 (2021)
  112. Tafazzoli A, "The potential value-based price of a multi-cancer early detection genomic blood test to complement current single cancer screening in the USA", Pharmacoeconomics, 40, pp.1107~1117 (2022)
  113. Zivanovic Bujak A, "Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology : a cohort study", PLoS Med, 17, pp.e1003363~ (2020)
  114. Lee J, "Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment : the VIKTORY Umbrella Trial", Cancer Discov, 9, pp.1388~1405 (2019)
  115. Berlanga P, "The European MAPPYACTS Trial : precision medicine program in pediatric and adolescent patients with recurrent malignancies", Cancer Discov, 12, pp.1266~1281 (2022)
  116. Sellami D, "Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes : a focus on PI3K inhibitors", Ann Oncol, 28, pp.2882~2887 (2017)
  117. Conforti F, "Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer : critical analysis of strengths, weaknesses, and misinterpretations", JAMA Oncol, 8, pp.1668~1675 (2022)
  118. Abbosh C, "ctDNA : an emerging neoadjuvant biomarker in resectable solid tumors", PLoS Med, 18, pp.e1003771~ (2021)
  119. Coakley M, "Molecular residual disease and adjuvant trial design in solid tumors", Clin Cancer Res, 25, pp.6026~6034 (2019)
  120. Kasi PM, "Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors", JCO Precis Oncol, 6, pp.e2100181~ (2022)
  121. Stadler JC, "Current and future clinical applications of ctDNA in immuno-oncology", Cancer Res, 82, pp.349~358 (2022)
  122. Snyder A, "Use of circulating tumor DNA for cancer immunotherapy", Clin Cancer Res, 25, pp.6909~6915 (2019)
  123. Bettegowda C, "Detection of circulating tumor DNA in early-and late-stage human malignancies", Sci Transl Med, 6, pp.224ra24~ (2014)
  124. Avanzini S, "A mathematical model of ctDNA shedding predicts tumor detection size", Sci Adv, 6, pp.eabc4308~ (2020)
  125. Bachet JB, "RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer : the AGEO RASANC prospective multicenter study", Ann Oncol, 29, pp.1211~1219 (2018)
  126. Bando H, "Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer", JCO Precis Oncol, 6, pp.e2100535~ (2022)
  127. Henriksen TV, "The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA", Mol Oncol, 14, pp.1670~1679 (2020)
  128. Razavi P, "High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants", Nat Med, 25, pp.1928~1937 (2019)
  129. Xiao W, "Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing", Nat Biotechnol, 39, pp.1141~1150 (2021)
  130. Moser T, "Bridging biological cfDNA features and machine learning appro-aches", Trends Genet, 39, pp.285~307 (2023)

관련 논문AI추천

Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays김영곤, 장자현, Cho Eun Hye, Hong Jinyoung, Kim Boram, Kim Yoonjung, Kong Sun-Young, Lee Jee Soo, Lee Seung-Tae, Lee Woochang, Shin Saeam, Song Eun Young대한진단검사의학회 · Annals of Laboratory Medicine2024 · 제44권 제3호Clinical Circulating Tumor DNA Testing for Precision Oncology김현지, 박경운대한암학회 · Cancer Research and Treatment2023 · 제55권 제2호Cell-Free DNA in Oncology: Gearing up for ClinicBryan C. Ulrich, Cloud P. Paweletz대한진단검사의학회 · Annals of Laboratory Medicine2018 · 제38권 제1호Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in NSCLC경동수, 김동완, 김미소, 김범석, 김태민, 김태유, 김황필, 노한성, 방두희, 육정환, 이한백, 임유주대한암학회 · Cancer Research and Treatment2024 · 제56권 제3호Current status and future perspectives of liquid biopsy in non-small cell lung cancer김완섭, 이창훈, 장선희, 최윤라, 허재영대한병리학회 · Journal of Pathology and Translational Medicine2020 · 제54권 제3호혈중 순환 종양 DNA 분석 임상 적용 가이드라인 소개Cho Eun Hye, Hong Jinyoung, Jang Ja-Hyun, Kim Boram, Kim Yoonjung, Kim Young-gon, Kong Sun-Young, Lee Jee Soo, Lee Seung-Tae, Lee Woochang, Shin Saeam, Song Eun Young대한진단검사의학회 · Laboratory Medicine Online2024 · 제14권 제3호

이 간행물의 다른 논문 (33건)

Clinical Circulating Tumor DNA Testing for Precision Oncology박경운, 김현지pp. 351-366Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020The Community of Population-Based Regional Cancer Registries, 서홍관, 윤이화, 김혜진, 임정수, 방소현, 최서현, 박은혜, 공현주, 정규원, 강미주pp. 385-399Prediction of Cancer Incidence and Mortality in Korea, 2023공현주, 서홍관, 김혜진, 윤이화, 박은혜, 임정수, 정규원, 강미주pp. 400-407Trends and Patterns of Cancer Burdens by Region and Income Level in Korea: A National Representative Big Data Analysis정윤선, 윤석준pp. 408-418Effectiveness of Self-Assessment, TAilored Information, and Lifestyle Management for Cancer Patients' Returning to Work (START): A Multi-center, Randomized Controlled Trial전미선, 김나연, 이정언, 허재성, 배가령, 이세경, 신동현, 조주희, 심영목, 강단비, 오승엽, 남석진, 안여진pp. 419-428
원문 보기